Skip Navigation


European Journal of Echocardiography Advance Access originally published online on July 18, 2008
European Journal of Echocardiography 2008 9(6):717-718; doi:10.1093/ejechocard/jen202
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
9/6/717    most recent
jen202v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Droogmans, S.
Right arrow Articles by Van Camp, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Droogmans, S.
Right arrow Articles by Van Camp, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Pergolide and valvular heart disease: the lower the better?

Steven Droogmans, Bernard Cosyns and Guy Van Camp*

Department of Cardiology, UZ Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium

* Corresponding author. Tel: +32 2 477 3252; fax: +32 2 477 6851. E-mail address: guy.vancamp@uzbrussel.be

The first 10% of the full text of this article appears below.

Recently, several publications have confirmed the association between pergolide use and valvular heart disease (VHD).1–3 The serotonin 2B (5HT2b) receptor has been proposed as the key pathway through which pergolide and other drugs activate valvular fibroblasts to proliferate and to produce myxoid substance and collagen, leading to valvular thickening and insufficiency.4 This can explain the occurrence of VHD with 5HT2b agonists such as pergolide and cabergoline, while drugs without 5HT2b activity have not been reported to cause valvulopathy (i.e. pramipexole, lisuride). . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J EchocardiogrHome page
S. Droogmans, D. Kerkhove, B. Cosyns, and G. Van Camp
Role of echocardiography in toxic heart valvulopathy
Eur J Echocardiogr, June 1, 2009; 10(4): 467 - 476.
[Abstract] [Full Text] [PDF]